
There are two types of Lymphomas – Hodgkins (rarer variety) and Non Hodgkins (more common variety). In the more common variety that affects the younger age group, the specialized immune cells B-cells (memory cells) and T-Cells (killer cells) are more affected.
Slow-growing, or indolent, non-Hodgkin lymphomas (affecting B and T-cells) are difficult to treat, with most patients relapsing repeatedly and the disease becomes increasingly resistant to therapy over time.But a new drug made by Seattle-based Gilead Sciences Inc. appears to offer hope for those fighting the disease.

The results were positive as tumour size shrunk by at least half in 57 percent of the patients and 6 percent had no measurable evidence of cancer. The drug had minor side effects like diarrhoea and colitis that can be avoided with few adjustments with the dosage.
The drug shows promise to be the standard therapy for Non Hodgkins Lymphomas in the coming years.
To know more about Lymphoma cancer treatment at World Class Hospitals in India, please visit this link : https://safemedtrip.com/medical-services/cancer-treatment-in-india/lymphoma-cancer-treatment-in-india.html